Literature DB >> 12166581

Correlation of inhaled nitric-oxide induced reduction of pulmonary artery pressure and vascular changes.

B H Jiang1, J Maruyama, A Yokochi, H Amano, Y Mitani, K Maruyama.   

Abstract

The purpose of the present study was to determine the relationship between hypertensive pulmonary vascular remodelling and the changes in mean pulmonary artery pressure (mPAP) during low-dose nitric oxide (NO) inhalation. Rats were exposed to chronic hypobaric hypoxia (air at 50.5 kPa (380 mmHg), 10% oxygen, for 5-29 days) to induce chronic pulmonary hypertension (PH) with pulmonary vascular structural changes. After the chronic hypoxic exposure, the rats had an indwelling pulmonary artery catheter inserted and changes in mPAP with NO were correlated to morphometrical analysis of pulmonary vascular changes. All concentrations of inhaled NO (0.1-2.0 parts per million) reduced mPAP with a similar per cent reduction from baseline mPAP in PH rats, while no changes were observed in control rats. During NO inhalation in PH rats, the absolute value of the decrease in mPAP, but not per cent reduction in mPAP, significantly correlated with baseline mPAP, the percentage of muscularised arteries at the alveolar wall level and at the alveolar duct level, and the per cent medial wall thickness of muscularised arteries. In the chronic hypoxic pulmonary hypertension model, the severity of pulmonary vascular remodelling did not alter the reactivity of the pulmonary arteries to nitric oxide and might, in part, determine the magnitude of nitric-oxide induced absolute reduction in mean pulmonary artery pressure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12166581     DOI: 10.1183/09031936.02.00249302

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  3 in total

Review 1.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.

Authors:  Emily J Tsai; David A Kass
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

2.  Formulation, preclinical and clinical evaluation of a new submicronic arginine respiratory fluid for treatment of chronic obstructive pulmonary disorder.

Authors:  Virendra Pratap Singh Rathor; Pradeep Chugh; Rashid Ali; Anuj Bhatnagar; Syed Ehtaishamul Haque; Aseem Bhatnagar; Gaurav Mittal
Journal:  Saudi Pharm J       Date:  2015-03-20       Impact factor: 4.330

3.  A novel inhibitor of inducible nitric oxide synthase, ONO-1714, does not ameliorate hypoxia-induced pulmonary hypertension in rats.

Authors:  Bao Hua Jiang; Junko Maruyama; Ayumu Yokochi; Yoshihide Mitani; Kazuo Maruyama
Journal:  Lung       Date:  2007-08-25       Impact factor: 3.777

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.